iMDx GraftAssure Shows Superior Sensitivity, 99.2% Concordance with Competitor in Peer-Reviewed Publication
IMDX has more than doubled off its 52-week low of $2.33.
Summary
Insight Molecular Diagnostics' GraftAssure assay achieved favorable head-to-head data published in Clinical Chemistry, showing 99.2% agreement with a leading NGS assay for kidney transplant rejection risk. The study also highlighted GraftAssure's superior analytical sensitivity, detecting donor-derived cell-free DNA at significantly lower quantities than competitors. This publication in a premier peer-reviewed journal provides strong scientific validation for the company's flagship product, which is critical for market adoption and regulatory efforts. This follows the company's March 8-K regarding FDA re-submission for GraftAssureDx. The company plans an upcoming regulatory submission in the EU and will present these findings at the American Transplant Congress from June 20-24.
At the time of this announcement, IMDX was trading at $5.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.8M. The 52-week trading range was $2.33 to $8.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.